AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
about
Signal transduction in the chronic leukemias: implications for targeted therapiesAdvances in targeting signal transduction pathwaysXenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agentsBcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationTwo hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Targeting AMPK for cancer prevention and treatment.miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML)Resveratrol and MalignanciesMetformin and its clinical use: new insights for an old drug in clinical practice.The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.Mitochondrial porin Por1 and its homolog Por2 contribute to the positive control of Snf1 protein kinase in Saccharomyces cerevisiae.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineMetformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cellsAll tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer.Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.The multiple mechanisms of cell death triggered by resveratrol in lymphoma and leukemia.Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.Cell death sensitization of leukemia cells by opioid receptor activationp53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice.Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling.Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.).Metformin and blood cancers
P2860
Q27026031-5DCFB48C-AD08-4BE5-8741-6E8249CC19B8Q27686983-B1CF5C34-3B13-44B2-BAB3-2349DEA37622Q28395443-5682E096-65B4-473F-8122-EF8198E78879Q30395557-D955335D-1276-4350-9362-9061A2F83E10Q33645356-6FC74AD4-F7AA-4EEB-BD21-DECF845F2453Q34260622-705B406C-A5F6-4CBE-B48B-B1C31250D795Q35781311-A2B10B93-AB3F-4696-AD6F-9031D5047956Q35839805-89062FF6-58E4-4617-8CC2-650D6247940CQ36165476-B1A7555E-FE08-4094-9883-C23DED69FF3EQ36423076-254C9785-152C-4B2E-86DC-C5DCD38896B6Q36426519-0D0C8622-D5F5-4460-94A4-2D3409A9D364Q36506529-9BD2731E-0377-4890-B3EF-DD9E73CE6122Q36556350-B8CDF9E9-B60B-4852-898A-AD4B0BC1E93EQ36604614-93A01780-9FEB-493B-A1C7-939FF3CAE923Q36919835-415663CC-44DA-48E0-B3A6-89F583FC4ED2Q36926106-E9C90B00-2924-478F-B694-4D3966D6A180Q36949580-92223A04-D55B-4DE9-9CFA-570B34C11C5DQ37530258-F28AEAC1-E53E-4241-AF72-4D0D704B21B4Q37649672-2A782A34-5A11-47BF-A1E3-38B40E182477Q37684132-8E294F09-70F6-49CF-B962-F650E5263095Q38764629-00365B3A-88C3-4D41-AA35-19AF376132E8Q39078119-B328F7BC-8EB0-41EC-9A20-56EB74AF5881Q39158015-A24F1428-C43B-4E5D-90F8-8989EB593144Q43249196-039D1BCD-D025-4326-A8D2-0B12D22FF401Q44147547-2FD58B6A-737C-427D-8539-935E01AFEC1BQ54948911-6F84A09D-9880-4FEE-9F31-ED62BCE23C52Q58699189-ADC39446-DFFE-48E0-9A31-74BAC79D2959
P2860
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@en
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@nl
type
label
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@en
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@nl
prefLabel
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@en
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@nl
P2860
P356
P1433
P1476
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
@en
P2093
Eliza Vakana
Leonidas C Platanias
P2860
P304
P356
10.18632/ONCOTARGET.413
P407
P5008
P577
2011-12-01T00:00:00Z